Enzymes continued

Other biomedical and biological appHcations of mictocapsules continue to be developed. For example, the encapsulation of enzymes continues to attract interest even though loss of enzyme activity due to harshness of the encapsulation protocols used has been a persistent problem (59). The use of mictocapsules in antibody hormone immunoassays has been reviewed (60). The encapsulation of hemoglobin as a ted blood substitute has received much attention because of AIDS and blood transfusions (61). 

US5344778 19 A process for reducing sulfur content Extract and/or enzymes Continuation in part of [52] [55]... 

Volume VI. Preparation and Assay of Enzymes (Continued) Preparation and Assay of Substrates Special Techniques... 

An immobilized-enzyme continuous-flow reactor incorporating a continuous direct electrochemical regeneration of NAD + has been proposed. To retain the low molecular weight cofactor NADH/NAD+ within the reaction system, special hollow fibers (Dow ultrafilter UFb/HFU-1) with a molecular weight cut-off of 200 has been used [32],... 

The number of known or presumed mononuclear, non-heme iron oxygenases and related enzymes continues to grow. This is due to intensive biochemical research and especially based on sequence data derived from genome research projects i.14). For several of these enzymes structural data are available by now from protein crystallography (12-14). In many of the iron oxygenases the iron is facially bound by two histidines and one carboxylate donor, either glutamic acid or aspartic acid. Thus, the term 2-His-l-carboxylate facial triad has been introduced by L. Que Jr. for this motif (19). 

Semibatch reactors are especially important for bioreactions, where one wants to add an enzyme continuously, and for multiple-reaction systems, where one wants to maximize the selectivity to a specific product. For these processes we may want to place one reactant (say, A) in the reactor initially and add another reactant (say, B) continuously. This makes Ca large at all times but keeps Cg small. We will see the value of these concentrations on selectivity and yield in multiple-reaction systems in the next chapter. 

Whelan and Bailey were also able to clarify the polymerization mechanism of the enzymatic polymerization with phosphorylase [124], Their results showed that the polymerization follows a multichain scheme in contrast to a single-chain scheme that was also proposed by some authors. In the multichain polymerization scheme, the enzyme-substrate complex dissociates after every addition step, whereas in the single-chain scheme each enzyme continuously increases the length of a single primer chain without dissociation. 

Table 2 A Labeling Examples of Drug-Drug Interactions (Evaluation of Drugs as Substrates for CYP Enzymes) Continued)...

As we noted in Chapter 16, the enzymes of many metabolic pathways are clustered (p. 605), with the product of one enzyme reaction being channeled directly to the next enzyme in the pathway. In the urea cycle, the mitochondrial and cytosolic enzymes appear to be clustered in this way. The citrulline transported out of the mitochondrion is not diluted into the general pool of metabolites in the cytosol but is passed directly to the active site of argininosuccinate synthetase. This channeling between enzymes continues for argininosuccinate, arginine, and ornithine. Only urea is released into the general cytosolic pool of metabolites. 

Note that even human tissues fixed immediately after their removal from the body may undergo cellular changes because usually the vascular supply is terminated before the tissue is surgically removed. During this duration ( 1 hr) the tissue remains at body temperature, at which the activity of digestive enzymes continues, damaging the cellular structures (Grizzle et al., 2001). 

Activity in the area of nonheme iron enzymes continues to flourish, with several exciting results being published in this subfield since Chapter 10 was submitted. 

The most commonly used therapy to treat LSDs is heterologous bone marrow transplantation (BMT). This treatment provides both normal bone marrow and bone marrow-derived cells, which release enzyme continuously. Unfortunately, BMT is associated with several problems and risks including the availability of a suitable donor, poor response to therapy, and sustained immune suppression. BMT therapies for MPS I, MPS II, MPS III, metachromatic leukodystrophy, and non-neuronopathic forms of Gaucher disease have demonstrated promising results. In most successful cases, the pathology is reversed in the visceral organs with variable or unclear success in the CNS (Laine et al., 2004). 

---